Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis

Veterinary and Comparative Orthopaedics and Traumatology

Volumn 24, Issue 4, 2011, Pages 279-284

  Isola, M ^a   Ferrari, V ^a   Miolo, Alda ^b   Stabile, F ^a   Bernardini, D ^a   Carnier, P ^a   Busetto, R ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Innovet Italia Srl   (Italy)

Author keywords

Canine osteoarthritis; Lameness; Nerve growth factor; Pain; Synovial fluid

Indexed keywords

NERVE GROWTH FACTOR;

AGING; ANIMAL; ANIMAL DISEASE; ANIMAL LAMENESS; ARTICLE; CHEMISTRY; DOG; DOG DISEASE; FEMALE; MALE; METABOLISM; OSTEOARTHRITIS; SYNOVIAL FLUID;

AGING; ANIMALS; DOG DISEASES; DOGS; FEMALE; LAMENESS, ANIMAL; MALE; NERVE GROWTH FACTORS; OSTEOARTHRITIS; SYNOVIAL FLUID;

CANIS FAMILIARIS;

EID: 79960879124     PISSN: 09320814     EISSN: None     Source Type: Journal    
DOI: 10.3415/VCOT-10-04-0051     Document Type: Article

References (42)

1. Johnston SA. Osteoarthritis. Joint anatomy, physiology, and pathobiology. Vet Clin North Am Small Anim Pract 1997; 27: 699-723.
2. Fox SM, Millis D. Osteoarthritis: the disease. In: Multimodal management of canine osteoarthritis. London: Manson Publishing Ltd; 2010. pg. 24-30.
3. Schaible HG, Richter F, Ebersberger A, et al. Joint pain. Exp Brain Res 2009; 196: 153-162.
4. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 2008; 22: 349-359.
5. McNamee KE, Burleigh A, Gompels LL. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain 2010; 149: 386-392.
6. Cohen S, Levi Montalcini R, Hamburger V. A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci 1954; 40: 1014-1018.
7. Aloe L, Levi-Montalcini R. The discovery of nerve growth factor and modern neurobiology. Trends Cell Biol 2004; 14: 395-399.
8. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci 2009; 20: 133-145.
9. Lewin GR, Ritter AM, Mendell LM. On the role of nerve growth factor in the development of myelinated receptors. J Neurosci 1992; 12: 1896-1905.
10. Levi Montalcini R, Aloe L, Alleva E. A role for nerve growth factor in nervous, endocrine and immune systems. Prog Neuroendommmmunol 1990; 3: 1-10.
11. Levi Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996; 19: 514-520.
12. Skaper SD. Nerve growth factor: a neurokine orchestrating neuroimmune-endocrine functions. Mol Neurobiol 2001; 24: 183-199.
13. Micera A, Puxeddu I, Aloe L et al. New insights on the involvement of nerve growth factor in allergic inflammation and fibrosis. Cytokine Growth Factor Rev 2003; 14: 369-374.
14. Nockler WA, Renz H. Neurotrophins in allergic diseases: from neuronal growth factors to intercellular signaling molecules. J Allergy Clin Immunol 2006; 117: 583-589.
15. Otten U, Marz P, Heese K, et al. Cytokines and neurotrophins interact in normal and diseased states. Ann NY Acad Sci 2000; 917: 322-330.
16. Leon A, Buriani A, Dal Toso R, et al. Mast cells synthesize, store and release nerve growth factor. Proc Natl Acad Sci 1994; 91: 3739-3743.
17. Kulka M, Sheen CH, Tancowny BP, et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008; 123: 398-410.
18. Bonini S, Rasi G, Bracci-Laudiero ML, et al. Nerve growth factor: neurotrophin or cytokine? Int Arch Allergy Immunol 2003; 131: 80-84.
19. Forsgren S. New data favouring that neurotrophins are of importance in arthritis. Arthritis Res Ther 2009; 11: 122.
20. Seidel MF, Herguijuela M, Forkert R, et al. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010; 40: 109-126.
21. Dicou E, Pierrot S. Nerve growth factor (NGF) autoantibodies and NGF in synovial fluid: implication in spondylarthropathies. Autoimmunity 1996; 24: 1-9.
22. Halliday DA, Zettler C, Robert A. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res 1998; 23: 919-922.
23. Aloe L, Manni L, Sebastiani G, et al. Nerve Growth Factor in the synovia of patients with rheumatoid arthritis: correlation with TNF-alpha and IL-1 beta and possible functional significance. Clin Exp Rheumatol 1999; 17: 632-633.
24. Iannone F, de Bari C, Dell'Accio F. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor in human osteoarthritic chondrocytes. Rheumatology 2002; 41: 1413-1418.
25. Shelton DL, Zeller J, Ho WH, et al. Nerve growth factor mediates hyperalgesia and cachexia in autoimmune arthritis. Pain 2005; 116: 8-16.
26. Iwakura N, Ohtori S, Orita S, et al. Role of low-affinity nerve growth factor receptor inhibitory antibody in reducing pain behavior and calcitonin gene-related peptide expression in a rat model of wrist joint inflammatory pain. J Hand Surg Am 2010; 35: 267-273.
27. Aloe L, Tuveri MA, Carcassi U, et al. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum 1992; 35: 351-355.
28. Aloe L, Probert L, Kollias G, et al. The synovium of transgenic arthritic mice expressing human necrosis factor contains a high level of nerve growth factor. Growth Factors 1993; 9: 149-155.
29. Barthel C, Yeremenko N, Jacobs R, et al. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arthritis Res Ther. 2009; 11: R82.
30. Raychaudhuri SP, Raychaudhuri SK. The regulatory role of nerve growth factor and its receptor system in fibroblast-like synovial cells. Scand J Rheumatol. 2009; 38: 207-215.
31. Rihl M, Kruithof E, Barthel C, et al. Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis 2005; 64: 1542-1549.
32. Manni L, Lundeberg T, Fiorito S, et al. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factoralpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheumatol. 2003; 21: 617-624.
33. Kapoor M, Martel-pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7: 33-42.
34. Hegemann N, Wondimu A, Kohn B, et al. Cytokine profile in canine immune-mediated polyarthritis and osteoarthritis. Vet Comp Orthop Traumatol 2005; 18: 67-72.
35. Fujita Y, Hara Y, Nezu Y, et al. Proinflammatory cytokine activities, matrix metalloproteinase-3 activity, and sulfated glycosaminoglycan content in synovial fluid of dogs with naturally acquired cranial cruciate ligament rupture. Vet Surg 2006; 35: 369-376.
36. Fox SM. Pathophysiology of osteoarthritic pain. In: Chronic pain in small animal medicine. London: Manson Publishing Ltd; 2010. pg. 74-96.
37. Ruiz G, Ceballos D, Banos JE. Behavioral and histological effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain. Brain Res 2004; 1011: 1-6.
38. Marchand F, Jones NG, McMahon SB. Future treatment strategies for neuropathic pain. Handb Exp Pharmacol 2009; 194: 589-615.
39. Pelegrini-da-Silva A, Oliveira MC, Parada CA, et al. Nerve growth factor acts with the beta2-adrenoceptor to induce spontaneous nociceptive behavior during temporomandibular joint inflammatory hyperalgesia. Life Sci 2008; 83: 780-785.
40. Comerford EJ, Smith K, Hayashi K. Update on the aetiopathogenesis of canine cranial cruciate ligament disease. Vet Comp Orthop Traumatol 2011; 24: 91-98.
41. Castaneda-Corral G, Jimenez-Andrade JM, Bloom AP, et al. The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience 2011; 178: 196-207.
42. Gordon WJ, Conzemius MG, Riedesel E, et al. The relationship between limb function and radiographic osteoarthrosis in dogs with stifle osteoarthrosis. Vet Surg 2003; 32: 451-454.